Database for Clinical and Anamnestic Data in Pulmonary Hypertension
Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg measured in the right heart catheterization.
There are different forms of PH defined in the classification of Dana Point 2008.
PH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like the echocardiography, stress echocardiography and cardio pulmonary exercise testing. In the diagnosis process and in the follow up of PH patients biomarkers like NTproBNP are helpful. There are no specific biomarkers for the disease which can make the diagnosis process easier and predict prognosis.
The systematic data collection in a data base provides better information about patients in daily routine and clinical studies as well as in the design of new studies.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Database for Clinical and Anamnestic Data in Pulmonary Hypertension|
- Collecting data in a PH patient database [ Time Frame: After one year: first analysis of retrospectivly collected data. Ongoing data collectioncontion: new data of patients who are allready in the database, new patients (3-4 years) ] [ Designated as safety issue: No ]Retrospective and prospective datainput and constant update
Biospecimen Retention: Samples With DNA
Blood samples are collected and stored anonymously in our biobank if patients give their informed consent containing the option of DNA analysis.
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||July 2017|
|Estimated Primary Completion Date:||July 2017 (Final data collection date for primary outcome measure)|
Patients of our outpatient clinic
Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
In this study the investigators want to collect clinical data of PH patients and controls in a database as well as blood samples in a biobank. The combination of anamnestic and clinical data and biomarkers should provide a better characterization of our patients and should improve the analysis of the disease development of different PH forms and therapeutic aspects.
After given informed consent patients' data are entered in a database at different time points. The database includes parameter of several invasive and non-invasive investigations like RHC, echocardiography, ECG, pulmonary function tests, cardiorespiratory exercise testing, 6-minute walk test, computed tomography, MRI, polysomnography, blood gas analysis and laboratory data as well as demographic data of the patients.
The blood samples are taken during routine punctuation and are stored in our biobank.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01607502
|Contact: Horst Olschewski, MDemail@example.com|
|Contact: Maria Tscherner, MDfirstname.lastname@example.org|
|Medical University of Graz||Recruiting|
|Graz, Austria, 8010|
|Contact: Horst Olschewski, MD +43-316-385-12183 email@example.com|
|Contact: Maria Tscherner, MD +43-316-385-12183 firstname.lastname@example.org|
|Principal Investigator: Horst Olschewski, MD|
|Principal Investigator:||Horst Olschewski, MD||Medical University of Graz|